Inventor
LAI KA-MAN VENUS
US55 patents
⚠️ This page may combine multiple inventors who share the name “LAI KA-MAN VENUS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
49 patentsUS9228208B2Jan 5, 2016
Methods and compositions for the targeted modification of a genome
REGENERON PHARMA79 citations98
US8697851B2Apr 15, 2014
MiRNA-regulated differentiation-dependent self-deleting cassette
REGENERON PHARMA91 citations98
US8354389B2Jan 15, 2013
miRNA-regulated differentiation-dependent self-deleting cassette
REGENERON PHARMA56 citations97
US10385359B2Aug 20, 2019
Targeted modification of rat genome
REGENERON PHARMA29 citations94
US10208317B2Feb 19, 2019
Methods and compositions for the targeted modification of a mouse embryonic stem cell genome
REGENERON PHARMA15 citations94
US9546384B2Jan 17, 2017
Methods and compositions for the targeted modification of a mouse genome
REGENERON PHARMA31 citations94
US10329582B2Jun 25, 2019
Genetic modification of rats
REGENERON PHARMA25 citations93
US9155290B2Oct 13, 2015
Humanized IL-15 animals
REGENERON PHARMA27 citations92
US8946505B2Feb 3, 2015
Promoter-regulated differentiation-dependent self-deleting cassette
REGENERON PHARMA10 citations92
US8946504B2Feb 3, 2015
Promoter-regulated differentiation-dependent self-deleting cassette
REGENERON PHARMA10 citations92
US9738897B2Aug 22, 2017
Nuclease-mediated DNA assembly
REGENERON PHARMA13 citations91
US10711280B2Jul 14, 2020
Methods and compositions for the targeted modification of a mouse ES cell genome
REGENERON PHARMA5 citations84
US10390522B2Aug 27, 2019
Non-human animals having a humanized programmed cell death 1 gene
REGENERON PHARMA6 citations84
US10301646B2May 28, 2019
Nuclease-mediated targeting with large targeting vectors
REGENERON PHARMA12 citations84
US9834786B2Dec 5, 2017
Nuclease-mediated targeting with large targeting vectors
REGENERON PHARMA13 citations84
US9410163B2Aug 9, 2016
Promoter-regulated differentiation-dependent self-deleting cassette
REGENERON PHARMA3 citations84
US9913461B2Mar 13, 2018
Genetically modified mouse whose genome comprises a humanized CD274 gene
REGENERON PHARMA4 citations83
US9267152B2Feb 23, 2016
MiRNA-regulated differentiation-dependent self-deleting cassette
REGENERON PHARMA4 citations83
US9096870B2Aug 4, 2015
miRNA-regulated differentiation-dependent self-deleting cassette
REGENERON PHARMA6 citations83
US9580715B2Feb 28, 2017
Nuclease-mediated DNA assembly
REGENERON PHARMA7 citations82
US10781453B2Sep 22, 2020
Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus
REGENERON PHARMA6 citations79
US10975390B2Apr 13, 2021
Targeted modification of rat genome
REGENERON PHARMA4 citations73
US10561125B2Feb 18, 2020
Humanized IL-15 animals
REGENERON PHARMA2 citations73
US10457960B2Oct 29, 2019
Methods and compositions for targeted genetic modification using paired guide RNAs
REGENERON PHARMA5 citations73
US11589562B2Feb 28, 2023
Mouse model of DITRA disease and uses thereof
REGENERON PHARMA2 citations72
US10894965B2Jan 19, 2021
Genetic modification of rats
REGENERON PHARMA2 citations72
US10881086B2Jan 5, 2021
Genetically modified mouse whose genome comprises a humanized CD274 gene
REGENERON PHARMA2 citations72
US10626402B2Apr 21, 2020
Nuclease-mediated DNA assembly
REGENERON PHARMA1 citations71
US10273488B2Apr 30, 2019
Nuclease-mediated DNA assembly
REGENERON PHARMA1 citations71
US10285388B2May 14, 2019
Non-human animals having a disruption in a C9ORF72 locus
REGENERON PHARMA2 citations70
US11820997B2Nov 21, 2023
Methods and compositions for the targeted modification of a genome
REGENERON PHARMA0 citations63
US12369570B2Jul 29, 2025
Humanized IL-15 animals
REGENERON PHARMA0 citations62
US12089575B2Sep 17, 2024
Genetically modified mouse that expresses humanized PD1 and PD-L1 proteins
REGENERON PHARMA0 citations62
US12065661B2Aug 20, 2024
Genetic modification of rats
REGENERON PHARMA0 citations62
US12037596B2Jul 16, 2024
Targeted modification of rat genome
REGENERON PHARMA0 citations62
US11697828B2Jul 11, 2023
Methods and compositions for targeted genetic modification using paired guide RNAs
REGENERON PHARMA1 citations62
US11684050B2Jun 27, 2023
Non-human animals having a humanized programmed cell death 1 gene
REGENERON PHARMA1 citations62
US11503813B2Nov 22, 2022
Humanized IL-15 animals
REGENERON PHARMA0 citations62
US11730150B2Aug 22, 2023
Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
REGENERON PHARMA0 citations61
US11547100B2Jan 10, 2023
Method for screening gene expression in lincRNA-deficient mice or rats
REGENERON PHARMA0 citations61
US10548302B2Feb 4, 2020
Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
REGENERON PHARMA1 citations61
US12419282B2Sep 23, 2025
Non-human animals expressing humanized CD3 complex
REGENERON PHARMA0 citations60
US11937587B2Mar 26, 2024
Non-human animals expressing humanized CD3 complex
REGENERON PHARMA0 citations60
US11932859B2Mar 19, 2024
Nuclease-mediated DNA assembly
REGENERON PHARMA0 citations60
US10932455B2Mar 2, 2021
Non-human animals expressing humanized CD3 complex
REGENERON PHARMA0 citations60
US11547101B2Jan 10, 2023
Non-human animals having a disruption in a C9ORF72 locus
REGENERON PHARMA0 citations59
US11470828B2Oct 18, 2022
Rodent model of mood disorders
REGENERON PHARMA1 citations59
US12471579B2Nov 18, 2025
Mouse model of DITRA disease and uses thereof
REGENERON PHARMA0 citations58
US10196613B2Feb 5, 2019
Stem cells for modeling type 2 diabetes
REGENERON PHARMA0 citations52
FRENDEWEY DAVID
1 patentShowing the top 50 of 55 patents by PatentIndex Score.